What You Need To Know
- Hackensack University Medical Center is the only site in New Jersey that is participating in the ROADSTER 3 clinical trial to assess real-world outcomes for patients with carotid artery disease who have an average surgical risk and undergo minimally invasive transcarotid artery revascularization (TCAR).
- Initially, TCAR was only approved for patients with carotid artery disease who were at high risk of experiencing surgical complications due to age, other medical conditions, or complex anatomy.
- The ROADSTER 3 trial examines the benefits of TCAR for patients with a standard surgical risk with the goal of expanding our ability to offer this procedure to a majority of patients with carotid artery disease.
- Hackensack Meridian Health vascular surgeons are among the most experienced in the region at performing TCAR.
Safer Alternative to Traditional Carotid Artery Revascularization Procedures
TCAR is an alternative to a carotid endarterectomy and transfemoral filter-protected stenting, both of which can carry a higher risk of stroke. And because it’s typically performed through a small incision near the treatment site using local anesthesia and light sedation, it’s an ideal option for patients who may be at high risk of complications related to general anesthesia or a more invasive procedure.
Nationally Recognized for TCAR Experience and Excellence
Under the leadership of David O’Connor, M.D., FACS, Director of Vascular Research at Hackensack University Medical Center and Assistant Professor of Surgery at Hackensack Meridian School of Medicine, Hackensack University Medical Center is the highest-volume TCAR center in New Jersey and among the highest-volume centers in the region.
HUMC has also been named a TCAR Center of Excellence by Silk Road Medical, the company that developed the TCAR procedure.